| Section | Status | NHS England | Name |
| 08.01.05 | Formulary |  |
Alectinib |
| 08.01.05 | Formulary | |
Arsenic Trioxide Trisenox® |
| 10.01.03 | Restricted Use | |
Avelumab Bavencio ® |
| 08.02.04 | Formulary | |
Axicabtagene ciloleucel YESCARTA® |
| 03.14 | Formulary | |
Benralizumab |
| 08.01.05 | Formulary | |
Brigatinib Alunbrig® |
| 04.08.01 | Formulary | |
Cannabidiol Epidyolex® |
| 08.01.05 | Formulary | |
Cemiplimab |
| 08.01.05 | Formulary | |
Ceritinib Zykadia® |
| 08.01.03 | Formulary | |
Cytarabine–daunorubicin liposomal Vyxeos® |
| 08.01.05 | Formulary | |
Dabrafenib with Trametinib |
| 08.01.05 | Formulary | |
Dacomitinib |
| 08.01.05 | Formulary | |
Daratumumab Darzalex ® |
| 08.02.03 | Formulary | |
Dinutuximab |
| 08.01.05 | Formulary | |
Durvalumab |
| 08.02.03 | Formulary | |
Gemtuzumab Mylotarg® |
| 05.03.03.02 | Formulary | |
Glecaprevir–pibrentasvir Maviret® |
| 08.01.05 | Formulary | |
Ibrutinib Imbruvica® |
| 08.02.03 | Formulary | |
Inotuzumab ozogamicin Besponsa ® |
| 08.01.05 | Restricted Use | |
Ixazomib |
| 03.04.03 | Formulary | |
Lanadelumab Takhzyro® |
| 08.01.05 | Formulary | |
Larotrectinib Vitrakvi® |
| 08.01.05 | Formulary | |
Lenvatinib Kisplyx ® |
| 05.03.02.02 | Formulary | |
Letermovir |
| 08.01.05 | Formulary | |
Lorlatinib Lorviqua® |
| 08.03.04.03 | Formulary | |
Lutetium (177Lu) oxodotreotide |
| 03.14 | Formulary | |
Mepolizumab (Nucala®) |
| 08.01.05 | Formulary | |
Midostaurin Rydapt® |
| 08.01.05 | Formulary | |
Neratinib Nerlynx® |
| 08.01.05 | Formulary | |
Niraparib |
| 10.02 | Formulary | |
Nusinersen |
| 08.02.03 | Formulary | |
Ocrelizumab |
| 08.02.04 | Formulary | |
Peginterferon beta-1a Plegridy ® |
| 03.11 | Restricted Use | |
Pirfenidone Esbriet® |
| 08.01.05 | Formulary | |
Rucaparib Rubraca® |
| 05.03.03.02 | Formulary | |
Sofosbuvir-velpatasvir-voxilaprevir |
| 09.05.02.02 | Formulary | |
Sucroferric oxyhydroxide Velphoro® |
| 08.01.05 | Formulary | |
Tisagenlecleucel Kymriah® |
| 08.01.05 | Formulary | |
Tivozanib Fotivda® |